GILT/IFI30 Antibody (MaP.IP30)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11217

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-11217
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Functional, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # MaP.IP30

Concentration

0.1 mg/ml

View all GILT/IFI30 Antibodies »

Product Specifications

Immunogen

Partial purified IP30 (purified from human B-LCL)

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for GILT/IFI30 Antibody (MaP.IP30)

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunoprecipitation

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
For Flow Cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 2ug/250000 cells.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

0.2 um filtered solution in PBS, 0.1% BSA

Preservative

0.02% Sodium Azide

Concentration

0.1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: GILT/IFI30

Antibodies derived from clone MAP.IP30 recognize human gamma-interferon-inducible lysosomal thiol reductase (GILT). GILT facilitates major histocompatibility complex (MHC) class II-restricted processing through reduction of protein disulfide bonds in the endocytic pathway. GILT can also facilitate the transfer of disulfide-containing antigens into the cytosol, enhancing their cross-presentation by MHC class I. Human GILT consists of 261 amino acids with a 37 amino acid signal sequence and a 224 amino acid precursor form. In general, the 35 kDa precursor is tagged with mannose-6- phosphate (M6P) residues and transported to the endocytic pathway via the M6P receptor (M6PR). A small fraction of the precursor is secreted as a disulfide-linked dimer. In early endosomes, N- and C-terminal pro-peptides are cleaved to generate a 28 kDa mature form. The mature form of GILT is localized to late endosomes and lysosomes and has maximal reductase activity at the acidic pH found in these compartments. GILT is constitutively expressed in professional antigen presenting cells (APC). The constitutive expression of GILT in APCs is likely to account for enhanced reduction of proteins in the late endosomal, lysosomal, and phagosomal compartments. A combination of GILT-mediated reduction and proteolysis in the these compartments can enhance the generation of class II epitopes as well as facilitate the translocation of internalized antigens into the cytosol for proteosomal processing and cross-presentation. The protein is also constitutively expressed in thymocytes, mature T cells, and some fibroblasts. IFN-g plays is the key factor in inducing expression of MHC class II and other components of the class II-restricted processing pathway. IFN-g signals through a specific cell surface receptor followed by activation of JAK/STAT1 signalling.

Long Name

Gamma-Interferon-inducible Lysosomal Thiol Reductase

Alternate Names

IFI30, IP30, Legumaturain

Gene Symbol

IFI30

Additional GILT/IFI30 Products

Product Documents for GILT/IFI30 Antibody (MaP.IP30)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for GILT/IFI30 Antibody (MaP.IP30)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.